Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 7, 1997, Pages 1566-1570

  Li, Ronald C ^a,b   Narang, Prem K ^b   Sahai, Jan ^c   Cameron, William ^c   Bianchine, Joseph R ^b  

^a Prince of Wales Hospital   (Hong Kong)

^b PFIZER INC   (United States)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DAPSONE; KETOCONAZOLE; RIFABUTIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS RELATED COMPLEX; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG SAFETY; DRUG SOLUBILITY; FEMALE; HUMAN; INTESTINE MUCOSA; MALE; MINIMUM INHIBITORY CONCENTRATION; PARTITION COEFFICIENT; PRIORITY JOURNAL; PROPHYLAXIS;

EID: 0030756976     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.7.1566     Document Type: Article

References (19)

1. Barry, M., J. L. Howe, S. Ormesher, D. J. Back, A. M. Breckenridge, C. Bergin, F. Mulcahy, N. Beeching, and F. Nye. 1994. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome. Br. J. Clin. Pharmacol. 37: 421-426.
2. Battaglia, R., E. Pianezzola, G. Salgarollo, G. Zini, and M. Strolin Benedetti. 1990. Absorption, disposition and preliminary metabolic pathway of 14C-rifabutin in animals and man. J. Antimicrob. Chemother. 26:813-822.
3. Check, W. 1996. New therapeutic approaches spark optimism among AIDS researchers: protease inhibitors, used with other antiviral agents, are changing the outlook for individuals infected with HIV. ASM News 62:637-639.
4. Dolin, R., J. S. Lambert, G. D. Morse, R. C. Reichman, C. S. Plank, J. Reid, C. Knupp, C. McLaren, and C. Pettinelli. 1990. 2′,3′-Dideoxyinosine in patients with AIDS or AIDS-related complex. Rev. Infect. Dis. 12(Suppl. 5):S540-S551.
5. Gibaldi, M., and D. Perrier. 1982. Noncompartmental analysis based on statistical moment theory, p. 409-416. In J. Swarbrick (ed.), Pharmacokinetics, 2nd ed. Marcel Dekker, Inc., New York, N.Y.
6. Hartman, N. R., R. Yarchoan, J. M. Pluda, R. V. Thomas, K. S. Marczyk, S. Broder, and D. G. Johns. 1990. Pharmacokinetics of 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin. Pharmacol. Ther. 47:647-654.
7. Knupp, C. A., F. M. Graziano, R. M. Dixon, and R. H. Barbhaiya. 1992. Pharmacokinetic-interaction study of didanosine and ranitidine in patients seropositive for human immunodeficiency virus. Antimicrob. Agents Chemother. 36:2075-2079.
8. Lewis, R. C., N. Z. Hatfield, and P. K. Narang. 1991. A sensitive method for quantitation of rifabutin and its desacetyl metabolite in human biological fluids by high-performance liquid chromatography (HPLC). Pharmaceut. Res. 8:1434-1440.
9. May, D. B., R. H. Drew, K. C. Yedinak, and J. A. Bartlett. 1994. Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers. Pharmacotherapy 14:509-513.
10. Narang, P. K. 1995. Clinical pharmacology of rifabutin: a new antimycobacterial. Rev. Contemp. Pharmacother. 6:129-151.
11. Nightingale, S. D., D. W. Cameron, F. M. Gordin, P. M. Sullam, D. L. Cohn, R. E. Chaisson, L. J. Eron, P. D. Sparti, B. Bihari, D. L. Kaufman, J. J. Stern, D. D. Pearce, W. G. Weinberg, A. LaMarca, and F. P. Siegal. 1993. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N. Engl. J. Med. 329:828-833.
12. Physicians' Desk Reference. 1995. VIDEX (Didanosine) package insert, p. 688. Medical Economics Data Production Company, Montvale, N.J.
13. Sahai, J., K. Gallicano, L. Oliveras, S. Khaliq, N. Hawley Foss, and G. Garber. 1993. Cations in the didanosine tablet reduce ciprofloxacin bioavailability. Clin. Pharmacol. Ther. 53:292-297.
14. Sahai, J., G. Garber, K. Gallicano, and W. Cameron. 1994. Effect of antacids in the didanosine (ddI) tablet on dapsone (DAP) absorption, abstr. A4. In Proceedings of the 34th Interscience Conference on Antimicrobial Agents Chemotherapy, 4 to 7 October, Orlando, Fla. American Society for Microbiology, Washington, D.C.
15. Skinner, M. H., M. Hsieh, J. Torseth, D. Pauloin, G. Bhatia, S. Harkonen, T. C. Merigan, and T. F. Blaschke. 1989. Pharmacokinetics of rifabutin. Antimicrob. Agents Chemother. 33:1237-1241.
16. Strolin-Benedetti, M., C. Efthymiopoulos, D. Sassella, E. Moro, and M. Repetto. 1990. Autoinduction of rifabutin metabolism in man. Xenobiotica 20:1113-1119.
17. Tamassia, V. 1986. A dose proportionality study of rifabutin in healthy volunteers given single oral doses (300, 450 and 600 mg). Internal report LM 427/610i. Farmitalia Carlo Erba, Milan, Italy.
18. Ungheri, D., G. Franceschi, and C. Della Bruna. 1986. Main human urinary metabolities of the spiropiperidyl rifamycin LM 427: isolation and biological properties, p. 1917-1918. In J. Ishigami (ed.), Recent advances in chemotherapy. University of Tokyo Press, Tokyo, Japan.
19. Vella, S. 1995. Rationale and experience with reverse transcriptase inhibitors and protease inhibitors. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 10(Suppl.):S58-S61.